The ability to go extended periods without hunger or eating, while pharmacologically useful for weight loss, can reinforce dangerous behaviors in vulnerable individuals
However, with IBD-current biologic therapies, all these mean some patients primary non-responders, experience a loss of response, intolerance or side effects, defining the urgent unmet need for novel treatments (13, 14)
2011, titled Contributions of serotonin in addiction vulnerability, shows low serotonin levels are significant predictive factors in identifying vulnerability to addiction
In addition, some of these products direct user to follow a potentially dangerous diet
a Randomised Evaluation) trial (547)